Randy Lindholm - Omnicell Independent Director
| OMCL Stock | USD 27.25 0.98 3.73% |
Director
Mr. Randy D. Lindholm is the Independent Director of Omnicell Inc. Since April 2002 Mr. Lindholm has served as a consultant to medical device companies. From June 1999 to April 2002 Mr. Lindholm was Chairman President and Chief Executive Officer of VidaMed Inc. a medical device company and from August 1998 to June 1999 served as its Executive Vice President Sales and Marketing. From 1993 to 1998 Mr. Lindholm held senior field operations positions at Nellcor Puritan Bennett a provider of solutions to diagnose monitor and treat respiratoryimpaired patients. Mr. Lindholm spent the previous 16 years at GE Medical Systems a medical device company. Mr. Lindholm received a B.S. in electrical engineering from Michigan Tech University. Mr. Lindholm is also a director of several privately held companies. since 2003.
| Age | 59 |
| Tenure | 21 years |
| Phone | 877 415 9990 |
| Web | https://www.omnicell.com |
Omnicell Management Efficiency
Omnicell's management efficiency ratios could be used to measure how well Omnicell manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Alex Mandl | R1 RCM Inc | 74 | |
| Diane Holder | Evolent Health | 70 | |
| Martin Harris | HealthStream | 61 | |
| Dale Polley | HealthStream | 67 | |
| Michael Kirshbaum | Evolent Health | 39 | |
| Brita Eilertsen | National Research Corp | 53 | |
| John Henneman | R1 RCM Inc | 56 | |
| William Stead | HealthStream | 69 | |
| Martiny Harris | HealthStream | 59 | |
| Diane Patrick | Agiliti | 69 | |
| Joseph Impicciche | R1 RCM Inc | 60 | |
| Charles Ditkoff | R1 RCM Inc | 55 | |
| Norman Payson | Evolent Health | 69 | |
| Matthew Hobart | Evolent Health | 47 | |
| Deborah Tate | HealthStream | 61 | |
| Michael Feiner | R1 RCM Inc | 75 | |
| JoAnn Martin | National Research Corp | 63 | |
| Bert Zimmerli | R1 RCM Inc | 65 | |
| Cheryl Scott | Evolent Health | 70 | |
| Bridget Duffy | Evolent Health | 60 | |
| Kjersti Kanne | National Research Corp | N/A | |
Management Performance
| Return On Equity | -0.0176 | ||||
| Return On Asset | -0.0061 |
Omnicell Leadership Team
Elected by the shareholders, the Omnicell's board of directors comprises two types of representatives: Omnicell inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Omnicell. The board's role is to monitor Omnicell's management team and ensure that shareholders' interests are well served. Omnicell's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Omnicell's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kathleen Nemeth, Senior Relations | ||
| Sara Dalmasso, Senior International | ||
| Jorge Taborga, Executive Vice President - Engineering | ||
| Daniel Johnston, Chief Admin. Officer, Chief Legal Officer, Executive VP and Corporate Secretary | ||
| Minoo Mortazavi, Senior Operations | ||
| Joanne Bauer, Independent Director | ||
| Christopher Drew, Executive VP of Sales and Marketing | ||
| James Judson, Lead Independent Director | ||
| Bruce Smith, Director | ||
| Sara White, Independent Director | ||
| Nchacha Etta, Executive CFO | ||
| Randall Lipps, Executive Chairman, CEO and Pres | ||
| Scott Seidelmann, Executive Vice President and Chief Commercial Officer | ||
| Maximo Rocha, Senior Officer | ||
| Robin Seim, Executive VP for International and Global Quality and Manufacturing | ||
| Giri Chodavarapu, Senior Officer | ||
| Vance Moore, Independent Director | ||
| Joseph Spears, Principal Chief Accounting Officer | ||
| Mark Parrish, Independent Director | ||
| Vicki MacDevitt, Chief Staff | ||
| Randy Lindholm, Independent Director | ||
| Corey Manley, Executive Officer | ||
| Bruce Scott, Independent Director | ||
| David Vanella, Senior Regulatory | ||
| Roxanne Turner, Sr Officer | ||
| Gary Petersmeyer, Independent Director | ||
| Christine Mellon, Chief VP | ||
| Peter Kuipers, CFO, Executive Vice President | ||
| Brian Nutt, Chief VP | ||
| Nhat Ngo, Executive VP of Strategy and Bus. Devel. |
Omnicell Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Omnicell a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0176 | ||||
| Return On Asset | -0.0061 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | (0.09) % | ||||
| Current Valuation | 1.37 B | ||||
| Shares Outstanding | 45.92 M | ||||
| Shares Owned By Insiders | 1.40 % | ||||
| Shares Owned By Institutions | 98.60 % | ||||
| Number Of Shares Shorted | 2.32 M | ||||
| Price To Earning | 64.95 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Omnicell. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Omnicell Stock please use our How to buy in Omnicell Stock guide.Note that the Omnicell information on this page should be used as a complementary analysis to other Omnicell's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Complementary Tools for Omnicell Stock analysis
When running Omnicell's price analysis, check to measure Omnicell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Omnicell is operating at the current time. Most of Omnicell's value examination focuses on studying past and present price action to predict the probability of Omnicell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Omnicell's price. Additionally, you may evaluate how the addition of Omnicell to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |
Is Omnicell's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Omnicell. If investors know Omnicell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Omnicell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Omnicell is measured differently than its book value, which is the value of Omnicell that is recorded on the company's balance sheet. Investors also form their own opinion of Omnicell's value that differs from its market value or its book value, called intrinsic value, which is Omnicell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Omnicell's market value can be influenced by many factors that don't directly affect Omnicell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Omnicell's value and its price as these two are different measures arrived at by different means. Investors typically determine if Omnicell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Omnicell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.